Cialis Clinical Trial

Clinical trials were released at the annual meeting of the Sexual Medicine Society in Denver. The data measured the effectiveness of Cialis in erectile dysfunction patients. Developed by Lilly ICOS, Cialis is a new investigational PDE5 inhibitor for the treatment of erectile dysfunction (ED). The study monitored 303 men.

Sixty-two percent of the men who underwent a surgery known as bilateral nerve-sparing radical retropubic prostatectomy had improved erections. (More than half of men who undergo the surgery experience some level of erectile dysfunction 18 months or more following the procedure.) Joel Kaufman, M.D., medical director of Urology Research Options says, "Despite numerous advances in the prostatectomy technique, data suggests that localized nerve trauma leaves many men with ED -- that is quite challenging to manage. In this trial, men taking Cialis reported an improvement in measures of improved erections, and maintaining erections for both penetration and completion of intercourse."

With the administration of 10mg or 20mg of Cialis, several medical findings were discovered:

1. Only 23 percent of men taking a placebo reported improved erections.
2. Over a 12-week period, eighty-two percent of men in the clinical trials attempted intercourse at least once between four hours and up to 36 hours after using Cialis.
3. In another round of clinical trials, 67 percent of the first time users with ED reported that intercourse was successful after taking Cialis.
4. A little over five percent of the patients experienced adverse effects during treatment with Cialis. The symptoms were headache, upset stomach and muscle ache.